1. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study. Issue 5 (3rd March 2022) Authors: Yamasaki, Kenshi; Yamanaka, Keiichi; Zhao, Yiwei; Iwano, Shunsuke; Takei, Keiko; Suzuki, Koji; Yamamoto, Toshiyuki Journal: Journal of dermatology Issue: Volume 49:Issue 5(2022) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study. Issue 12 (17th August 2020) Authors: Yamasaki, Kenshi; Yamanaka, Keiichi; Zhao, Yiwei; Iwano, Shunsuke; Takei, Keiko; Suzuki, Koji; Yamamoto, Toshiyuki Journal: Journal of dermatology Issue: Volume 47:Issue 12(2020) Page Start: 1383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results. Issue 1 (7th October 2020) Authors: Morita, Akimichi; Takahashi, Hidetoshi; Ozawa, Kentaro; Imafuku, Shinichi; Takekuni, Nakama; Takahashi, Kenzo; Matsuyama, Takashi; Okubo, Yukari; Zhao, Yiwei; Kitamura, Susumu; Takei, Keiko; Yokoyama, Masayuki; Hayashi, Nobukazu; Terui, Tadashi Journal: Journal of dermatology Issue: Volume 48:Issue 1(2021) Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗